Eliem Therapeutics, Inc. (NASDAQ:ELYM – Get Free Report) shares dropped 1.5% during trading on Thursday . The stock traded as low as $11.90 and last traded at $12.11. 895,257 shares were traded during trading, an increase of 84% from the average daily volume of 486,688 shares. The stock had previously closed at $12.29.
Eliem Therapeutics Stock Performance
The company has a 50 day moving average of $12.15 and a 200 day moving average of $8.89. The stock has a market capitalization of $360.30 million, a price-to-earnings ratio of -22.85 and a beta of -0.39.
Eliem Therapeutics Company Profile
Eliem Therapeutics, Inc is a clinical‐stage biotechnology company focused on the development of novel therapeutics for the treatment of neurological and neuropsychiatric disorders. The company’s scientific approach is centered on proprietary peptide and small‐molecule drug candidates designed to modulate central nervous system pathways. By leveraging targeted delivery and receptor‐specific activity, Eliem seeks to address unmet medical needs in areas such as pain management, spasticity and other debilitating sequelae of spinal cord injury.
The company’s most advanced program, ELI-200, is being investigated as a potential treatment for spasticity and neuropathic pain associated with spinal cord injury.
Further Reading
- Five stocks we like better than Eliem Therapeutics
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Receive News & Ratings for Eliem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eliem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
